Ocular Therapeutix (OCUL)
(Delayed Data from NSDQ)
$8.03 USD
-0.34 (-4.06%)
Updated Aug 8, 2024 04:00 PM ET
After-Market: $8.04 +0.01 (0.12%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth F Momentum F VGM
Brokerage Reports
Ocular Therapeutix, Inc. [OCUL]
Reports for Purchase
Showing records 61 - 80 ( 89 total )
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
sNDA for Ocular Inflammation Approved; Formal Launch of DEXTENZA In a Week; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Reimbursement Code and Pass-through Status Approved for DEXTENZA; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
OTX-TP Missed Primary Endpoint in Phase 3 Glaucoma Study; Reiterate Buy; Lower Price Target to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
1Q19 Financial Results Reported; DEXTENZA Launch Imminent; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
ARVO 2019 Conference Highlights: Next-Generation Ophthalmology Therapeutics Emerge
Provider: H.C. Wainwright & Co., Inc.
Analyst: CHEN Y
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
DEXTENZA Receives J-Code Recommendation; Preliminary OTX-TIC Phase 1 Trial Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
DEXTENZA sNDA for Ocular Inflammation Accepted; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
R-D Day Focuses on Adoption of DEXTENZA in Real-World Practice; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2018 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
First Wet AMD Patient Dosed With OTX-TKI in Phase 1 Trial; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
DEXTENZA sNDA Submitted to Add Post-Operative Inflammation on Label; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Research Collaboration in Non-opioids for Pain; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
FDA Approves Dextenza Ahead of PDUFA Date; Reiterate Buy; Raising Price Target to $12
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
A J-code for DEXTENZA Highly Likely; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
3Q Financial Results; Facility Inspection Completed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
ReSure Warning Letter Insignificant to Pipeline; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
Hydrogel IP License Expanded; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
2Q18 Financial Results Reported; Dextenza Approval Decision Date Approaching; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Ocular Therapeutix, Inc.
Industry: Medical - Drugs
FDA Accepts Dextenza NDA; PDUFA Date December 28, 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R